Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Immunol ; 95: 1-9, 2018 03.
Article in English | MEDLINE | ID: mdl-29367080

ABSTRACT

We have previously generated human IgG1 antibodies that were engineered for reduced binding to the classical Fcγ receptors (FcγRI-III) and C1q, thereby eliminating their destructive effector functions (constant region G1Δnab). In their potential use as blocking agents, favorable binding to the neonatal Fc receptor (FcRn) is important to preserve the long half-life typical of IgG. An ability to cross the placenta, which is also mediated, at least in part, by FcRn is desirable in some indications, such as feto-maternal alloimmune disorders. Here, we show that G1Δnab mutants retain pH-dependent binding to human FcRn but that the amino acid alterations reduce the affinity of the IgG1:FcRn interaction by 2.0-fold and 1.6-fold for the two antibodies investigated. The transport of the modified G1Δnab mutants across monolayers of human cell lines expressing FcRn was approximately 75% of the wild-type, except that no difference was observed with human umbilical vein endothelial cells. G1Δnab mutation also reduced transport in an ex vivo placenta model. In conclusion, we demonstrate that, although the G1Δnab mutations are away from the FcRn-binding site, they have long-distance effects, modulating FcRn binding and transcellular transport. Our findings have implications for the design of therapeutic human IgG with tailored effector functions.


Subject(s)
Histocompatibility Antigens Class I/metabolism , Immunoglobulin G/metabolism , Placenta/metabolism , Receptors, Fc/metabolism , Cells, Cultured , Female , Histocompatibility Antigens Class I/chemistry , Histocompatibility Antigens Class I/genetics , Human Umbilical Vein Endothelial Cells , Humans , Immunoglobulin G/chemistry , Immunoglobulin G/genetics , Kinetics , Maternal-Fetal Exchange/physiology , Models, Molecular , Mutant Proteins/chemistry , Mutant Proteins/metabolism , Mutation , Pregnancy , Protein Binding , Receptors, Fc/chemistry , Receptors, Fc/genetics , Receptors, IgG/metabolism
2.
Reproduction ; 133(3): 653-61, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17379659

ABSTRACT

Glucocorticoids play a critical role in fetal development, but inappropriate exposure is associated with reduced fetal growth. We investigated cortisol exposure and supply in a porcine model of differential fetal growth. This model compares the smallest fetus of a litter with an average-sized sibling at three stages of gestation. At day 45, small fetuses had reduced plasma cortisol (16.8 +/- 3.4 ng/ml) relative to average fetuses (34.4 +/- 3.4 ng/ml, P < 0.001). At day 65 levels had reduced in small and average fetuses to similar concentrations (5.7 +/- 1.0 vs 4.8 +/- 0.5 ng/ml, P = 0.128). By day 100, elevated levels were found in small fetuses (10.7 +/- 1.5 vs 7.6 +/- 0.7 ng/ml, P < 0.001). Maternal plasma cortisol was unchanged over gestation (day 45, 56.7 +/- 21.6 ng/ml; day 65, 57.8 +/- 14.4 ng/ml; day 100, 55.7 +/- 6.5 ng/ml). We examined the cause of altered cortisol by investigating the fetal hypothalamic-pituitary-adrenal axis through the measurement of adrenocorticotropic hormone and assessing exposure to maternal cortisol by quantifying placental 11beta-hydroxysteroid dehydrogenase-isoform 2 (11beta HSD-2) gene expression. These data suggest that altered cortisol supply was of fetal origin. We examined organ glucocorticoid (GC) metabolism by the measurement of GC receptor (GR) and 11beta-hydroxysteroid dehydrogenase-isoform 1 (11beta HSD-1) gene expression. We found that fetal organs have different temporal patterns of 11beta HSD-1 and GR expression, with the liver particularly sensitive to cortisol in late gestation. This study examines GC exposure in naturally occurring differential growth and simultaneously explores tissue GC sensitivity and handling, at three key stages of gestation.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenases/analysis , Hydrocortisone/blood , Maternal-Fetal Exchange , Pituitary-Adrenal System/embryology , Receptors, Glucocorticoid/analysis , Swine/embryology , 11-beta-Hydroxysteroid Dehydrogenase Type 1/analysis , 11-beta-Hydroxysteroid Dehydrogenase Type 1/genetics , 11-beta-Hydroxysteroid Dehydrogenase Type 2/analysis , 11-beta-Hydroxysteroid Dehydrogenase Type 2/genetics , 11-beta-Hydroxysteroid Dehydrogenases/genetics , Adrenocorticotropic Hormone/blood , Animals , Biomarkers/analysis , Blotting, Northern/methods , Body Weight , Female , Fetal Blood/chemistry , Fetal Development/physiology , Gene Expression , Gestational Age , Liver/chemistry , Models, Biological , Pregnancy , RNA, Messenger/analysis , Receptors, Glucocorticoid/metabolism , Reverse Transcriptase Polymerase Chain Reaction
3.
Reproduction ; 129(6): 757-63, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15923391

ABSTRACT

The fetus requires an adequate supply of fatty acids for optimum growth and development. It has been hypothesized that reduced activity of enzymes of fatty acid metabolism could contribute to inadequate fetal growth. In a porcine model of differential fetal growth we examined heart and liver fatty acid synthase, delta5-desaturase and delta6-desaturase gene expression and measured hepatic fatty acid profile to assess long-chain polyunsaturated fatty acid status. On gestation days 45, 65 and 100 sows were killed and tissues extracted from an average-sized fetus and the smallest fetus from each litter. As early as day 45, considerable hepatic delta5- and delta6-desaturase was detected, and this expression significantly increased as gestation progressed. In contrast, cardiac desaturase expression remained stable with time. Fatty acid synthase expression was greatest at day 65 in the liver, but was not expressed in the heart. Overall, the smallest fetus did not exhibit reduced tissue delta5- or delta6-desaturase expression or compromised polyunsaturated fatty acid status at any stage. In fact, small fetuses expressed more cardiac delta5-desaturase than their average-sized siblings, possibly in response to a stress to the heart. It is clear from this study that fatty acid metabolism changes markedly as gestation progresses, and reduced fatty acid supply does not cause inadequate growth in this porcine model of fetal development.


Subject(s)
Embryo, Mammalian/anatomy & histology , Embryonic Development , Fatty Acids/metabolism , Animals , Delta-5 Fatty Acid Desaturase , Embryo, Mammalian/metabolism , Fatty Acid Desaturases/analysis , Fatty Acid Synthases/analysis , Fatty Acids/analysis , Female , Gestational Age , Linoleoyl-CoA Desaturase , Liver/enzymology , Models, Animal , Myocardium/enzymology , Pregnancy , Swine
4.
Reproduction ; 128(2): 229-35, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15280562

ABSTRACT

Low birth weight is a major factor in neonatal morbidity and mortality in humans and domestic species and is a predictor of physiological disorders in adulthood. This study utilised the naturally occurring variation in pig fetal size within a uterus to test the hypothesis that placental amino acid transport capability is associated with fetal growth. Leucine uptake by trophoblast vesicles prepared from placentas supplying an average-sized fetus and the smallest fetus in the uterus was assessed. On days 45 and 65 of gestation, uptake of leucine by the porcine placenta was predominantly sodium independent and was inhibited by the non-metabolised leucine analogue 2-amino-2-norbornane-carboxylic acid, indicating that uptake occurs via system L. By day 100 the uptake of leucine by placentas supplying average-sized fetuses had changed from being predominantly sodium independent to involving both sodium-dependent (system B0) and -independent (system L) pathways. This change was not seen in placentas supplying the smallest fetus, which continued to display predominantly sodium-independent uptake. In conclusion, these data show gestational- and fetal size-dependent changes in the transport of leucine across the porcine placenta.


Subject(s)
Fetal Growth Retardation/metabolism , Leucine/metabolism , Placenta/metabolism , Signal Transduction/physiology , Animals , Biological Transport/physiology , Birth Weight , Female , Gestational Age , Models, Animal , Pregnancy , Sodium/metabolism , Swine
6.
J Med Chem ; 45(11): 2173-84, 2002 May 23.
Article in English | MEDLINE | ID: mdl-12014955

ABSTRACT

Previously we reported the identification of RPR200765A, a potent orally bioavailable pyridine-imidazole inhibitor of p38 mitogen-activated protein (MAP) kinase which suppressed paw swelling and joint pathology in streptococcal cell wall-induced arthritis. Herein, we report the use of solid-phase combinatorial organic synthesis for the parallel processing of a related pyrimidine-imidazole-based library with two points of structural variability. We report also that the application of a computer algorithm, the Monte Carlo Monomer Selection, maximized both the combinatorial synthetic efficiency and the bioavailability of the final compounds. In conjunction with the synthetic protocols, the polymer-supported quench technique was applied to the purification of the final compounds. Through rapid evaluation of the library using a p38 kinase assay and permeability assays, it was possible to identify a number of potent and orally bioavailable p38 MAP kinase inhibitors suitable for further biological investigation.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Dioxanes/chemical synthesis , Enzyme Inhibitors/chemical synthesis , Imidazoles/chemical synthesis , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Piperazines/chemical synthesis , Pyrimidines/chemical synthesis , Administration, Oral , Algorithms , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arthritis, Experimental/blood , Arthritis, Experimental/drug therapy , Biological Availability , Caco-2 Cells , Cell Line , Combinatorial Chemistry Techniques , Dioxanes/pharmacokinetics , Dioxanes/pharmacology , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans , Imidazoles/chemistry , Imidazoles/pharmacokinetics , Mice , Mice, Inbred BALB C , Monocytes/metabolism , Monte Carlo Method , Piperazines/pharmacokinetics , Piperazines/pharmacology , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Rats , Rats, Inbred Lew , Structure-Activity Relationship , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases
7.
Am J Physiol Cell Physiol ; 282(3): C472-8, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11832331

ABSTRACT

We previously reported an endogenous, membrane-bound Cu oxidase with homology to ceruloplasmin in BeWo cells, a placental choriocarcinoma cell line. In this previous study, ceruloplasmin immunoreactivity was localized to the perinuclear region and non-brush-border membranes. Here, we show that azide-sensitive oxidase activity is enriched in the same fractions, correlating subcellular localization of enzyme activity with ceruloplasmin immunoreactivity. Expression of the placental Cu oxidase is inversely proportional to Fe status and directly proportional to Cu status at enzyme and protein levels. To identify a role for the Cu oxidase, cells were exposed to (59)Fe-transferrin for 18 h in an environment of 20% O(2) or 5% O(2). At 5% O(2), Cu-deficient cells retain significantly more (59)Fe than control cells. This excess in (59)Fe accumulation is caused by a significant decrease in (59)Fe release. These results indicate that downregulation of the placental Cu oxidase in BeWo cells impairs Fe release. This effect is only apparent in an environment of limited O(2).


Subject(s)
Ceruloplasmin/metabolism , Copper/metabolism , Iron/metabolism , Phenylenediamines/metabolism , Placenta/enzymology , Sarcosine/analogs & derivatives , Animals , Cell Fractionation , Ceruloplasmin/analogs & derivatives , Choriocarcinoma , Deferoxamine/pharmacology , Female , Heterocyclic Compounds/pharmacology , Humans , Iron Chelating Agents/pharmacology , Oxidoreductases/metabolism , Oxygen/metabolism , Placenta/cytology , Placenta/drug effects , Pregnancy , Sarcosine/pharmacology , Tumor Cells, Cultured , Uterine Neoplasms
SELECTION OF CITATIONS
SEARCH DETAIL
...